HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?

HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?

Assessment of homologous recombination deficiency (HRD) status is now essential for ovarian cancer patient management. The aim of our study was to analyze the influence of ethnic variations, tumor purity, and neoadjuvant chemotherapy (CT) on the determination of HRD scores as well as to evaluate fea...

Full description

Bibliographic Details
Main Authors: Tatiana Kekeeva, Yulia Andreeva, Alexander Tanas, Alexey Kalinkin, Svetlana Khokhlova, Tatiana Tikhomirova, Alexandra Tyulyandina, Anatoly Popov, Maria Kuzmenko, Mikhail Volkonsky, Natalia Chernorubashkina, Valeria Saevets, Vadim Dmitriev, Valentina Nechushkina, Olga Vedrova, Sergei Andreev, Sergey Kutsev, Vladimir Strelnikov
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:International Journal of Molecular Sciences
Subjects:
homologous recombination deficiency
<i>BRCA</i> mutation
genomic instability score
tumor purity
pathological response
Online Access:https://www.mdpi.com/1422-0067/24/13/10497

Internet

https://www.mdpi.com/1422-0067/24/13/10497

Similar Items